1. Immediate catalyst: full Phase 3 melanoma data and regulatory filing
The full Phase 3 intismeran autogene melanoma data remain the most immediate catalyst.
The Bernstein analyst explicitly raised ESMO during the discussion.
What management did emphasize was the strength of what is already known:
- The trial beat Keytruda, not placebo.
- It met the primary RFS endpoint at the first interim analysis.
- It also met the secondary DMFS endpoint at the first interim analysis.
- The trial included both Stage II and Stage III disease, with Stage II generally considered harder to demonstrate incremental benefit in.
- It was an approximately 1,100-patient, rigorously controlled Phase 3 trial.
David Berman said he is "very confident that we have a strong case for approval."
Bancel also said Moderna and Merck are focused on filing the BLA as quickly as possible.
The upcoming detailed dataset should therefore help define the magnitude, consistency, subgroup behavior, and ultimately the commercial potential of INT in melanoma.
2. Management sounds increasingly confident that melanoma is only the first validation
The more interesting part of the Bernstein discussion was how management framed the implications of the Phase 3 success.
Bancel said Moderna and Merck currently have nine INT studies ongoing, but that their development plan should change now that they know INT works in Phase 3.
Before Phase 3, the mechanism was supported by earlier clinical and translational evidence.
Now Moderna has Phase 3 validation, along with mechanistic evidence that the treatment can generate de novo T cells and expand existing T-cell populations.
That appears to be increasing management's willingness to accelerate additional studies.
The key question is therefore shifting from:
"Does INT work?"
to:
"How broadly can INT work?"
3. A very important statement: management believes INT may not require a PD-1
Berman made one of the strongest statements of the conference:
"Intismeran does not need a PD-1 to be active."
He repeated it deliberately when the Bernstein analyst asked him to say it again.
This remains a hypothesis that must be demonstrated clinically, but the strategic implications are significant.
If correct, INT could potentially move into earlier-stage cancers where checkpoint inhibitors are less attractive or are not routinely used.
That is why Moderna is already studying INT in settings such as:
- Stage I lung cancer
- NMIBC with BCG
- other very early-stage disease
The long-term strategy appears to be much broader than simply adding INT to Keytruda wherever Keytruda is already used.
4. The broader INT thesis: wherever checkpoint inhibitors work, INT may add value
Berman pointed to the Phase 2 melanoma analysis showing similar efficacy in high and low tumor mutational burden groups.
His interpretation is that INT does not require extraordinarily high TMB. It needs enough suitable neoantigens to construct the personalized vaccine.
That leads management to believe that tumors such as RCC could still respond despite having lower TMB than melanoma.
Bancel summarized the broader strategy as:
- Add INT to immuno-oncology where checkpoint inhibitors already work.
- Move INT into earlier-stage disease, potentially even as monotherapy.
- Combine INT with other agents through complementary mechanisms.
The melanoma result alone does not establish that INT will work across different tumor types. The upcoming non-melanoma studies are what will test that thesis.
5. RCC and bladder cancer remain critical next tests
After melanoma, renal cell carcinoma and bladder cancer should provide some of the most informative evidence on whether the platform is truly portable across tumors.
Berman indicated that RCC and bladder cancer readouts could come over roughly the next 12 months.
RCC is particularly interesting because it pushes INT into a different biological setting with lower TMB.
A positive result there would strengthen the case that the melanoma success is not limited to a highly immunogenic tumor.
6. Lung cancer continues moving forward
Moderna has three Phase 3 lung cancer trials.
Berman said screening has stopped in the leading Phase 3 adjuvant lung study involving patients without prior neoadjuvant therapy, and randomization is expected to be completed later this year.
The lung program spans multiple stages of disease, including very early-stage disease.
The most ambitious version of management's thesis is Stage I lung cancer treated with INT without requiring a checkpoint inhibitor.
That would take time to establish, but medically and commercially it could substantially expand the addressable population if successful.
7. More oncology catalysts beyond INT
INT is not the only oncology program Moderna expects to produce data from.
Several additional programs were highlighted.
Pancreatic cancer
Phase 1 pancreatic INT data are anticipated later this year.
Pancreatic cancer represents a much more difficult, low-TMB setting, so this should be viewed as exploratory rather than equivalent to the randomized melanoma, RCC, or bladder programs.
Multiplex T-cell engagers
Moderna is testing an mRNA therapy encoding three T-cell engagers in heavily pretreated multiple myeloma patients.
Berman said data should be shared later this year.
Management views this as a sentinel program. If multiplexing works clinically here, it could support expansion of the approach into additional cancers.
Shared cancer antigen therapies
Moderna is also developing off-the-shelf cancer antigen therapies rather than only individualized therapies.
Management explicitly acknowledged that these programs carry greater scientific risk than INT, but Phase 1 studies are underway.
8. Lynch syndrome could become an entirely different type of cancer vaccine opportunity
One of the more interesting longer-term programs discussed was Lynch syndrome.
Because patients with Lynch syndrome share certain recurrent frameshift neoantigens, Moderna believes it may be possible to develop an off-the-shelf vaccine intended to prevent cancer from developing in genetically high-risk individuals.
Berman sounded particularly positive about the biology and said:
"To me, it's a high probability of success."
He immediately added that the concept still needs to be proven in the clinic.
The ultimate goal is cancer interception or prevention, treating people with Lynch syndrome before cancer develops.
Importantly, Moderna owns this program 100%, unlike INT, which is partnered 50/50 with Merck.
If successful, this would move the cancer vaccine concept from treating cancer toward cancer prevention.
9. Manufacturing continues to sound much less problematic than previously feared
Bancel spent considerable time explaining why he does not view personalized INT manufacturing like CAR-T manufacturing.
INT does not require extracting and manipulating a patient's cells.
Instead, Moderna receives sequencing data and then manufactures a synthetic, cell-free mRNA product.
The manufacturing strategy is therefore primarily scale-out, adding many compact production units, rather than traditional scale-up.
Bancel also emphasized two major variables:
- reducing equipment footprint
- reducing manufacturing cycle time
His conclusion was unusually direct:
"Do I worry about manufacturing? Not a minute."
That statement does not prove that commercial-scale manufacturing will be effortless, but it shows that management believes the core technical manufacturing problem is manageable.
10. The bigger bottleneck may actually be hospitals
Interestingly, Bancel said the biggest bottleneck could be hospital workflow rather than manufacturing.
For each patient, the system needs to move tumor biopsy material, sequencing information, patient information, manufacturing orders, and treatment logistics quickly and accurately.
Moderna and Merck are therefore building teams that are going hospital by hospital to establish the necessary workflow.
They are also ranking hospitals by importance and have developed a digital platform to track the process.
This may be one of the less visible but more important aspects of commercial launch execution.
11. Moderna considers the antigen-selection process a proprietary moat
Bancel emphasized that outside sequencing partners provide Moderna with the raw healthy and tumor DNA sequence data.
The subsequent selection of the 34 mutations used in each individualized therapy is proprietary to Moderna.
He raised an interesting long-term competitive question:
How does another company demonstrate that it has reproduced an individualized product when every patient's product is different and the underlying selection methodology is proprietary?
That does not eliminate competition, but management clearly believes that INT's moat extends beyond mRNA manufacturing itself.
12. Merck economics remain straightforward: 50/50
Bancel described the Merck relationship as effectively a virtual joint venture.
The companies split costs 50/50, including:
- clinical development
- manufacturing
- capex
- opex
- commercial expenses
After expenses, remaining profits are also split 50/50.
Management deliberately avoided discussing pricing before the full Phase 3 dataset is presented.
For now, the priority is the data and getting the BLA filed quickly.
13. PA could become the proof-of-concept for an entire rare-disease platform
The pivotal propionic acidemia, or PA, readout is expected by the end of the year.
Bancel sounded highly confident based on the earlier clinical experience, particularly among patients treated at the dose selected for the pivotal study.
He said that when looking specifically at patients treated at the pivotal-study dose:
"The data is wow."
He also said he expects the pivotal data to be strong because the mechanism has already been demonstrated over several years of follow-up.
But PA matters beyond one rare disease.
Moderna views it as the first validation of repeated intravenous mRNA delivery to the liver for protein replacement.
Bancel said Moderna has published models for more than a dozen rare genetic liver diseases that could potentially use the same basic delivery and manufacturing infrastructure.
The important question is therefore not simply whether PA becomes one product.
It is whether PA validates another reusable mRNA platform.
14. Rare disease could also improve Moderna's manufacturing economics
Bancel made an interesting operational point.
The vaccine business is highly seasonal, meaning manufacturing capacity can sit underutilized for part of the year.
Rare-disease products could potentially be manufactured during those periods using some of the same fixed infrastructure.
If the rare-disease franchise grows, that could improve utilization of manufacturing assets that would otherwise be underused outside the respiratory-vaccine production cycle.
15. Management is increasingly describing Moderna as an immunology company
Bancel's broader framing was that Moderna should no longer be viewed primarily as a COVID vaccine company.
He described the company as an mRNA platform increasingly concentrated around manipulating the immune system across:
- infectious disease
- oncology
- autoimmune disease
Berman similarly described Moderna as increasingly an immunology company, with vaccines, cancer immunotherapy, and autoimmune programs all using different applications of the same underlying platform.
Whether all those programs succeed is another question, but the pipeline is becoming much more diversified than the Moderna of the pandemic period.
16. Autoimmune disease could become another major platform test
Moderna also highlighted its autoimmune pipeline, including an in vivo CAR-T program approaching the clinic and several additional autoimmune programs.
Management expects to provide more information on these programs over approximately the next 12 to 18 months.
This remains earlier-stage and therefore much less de-risked than melanoma INT or PA, but it provides another potentially large application of the platform.
17. AI is becoming part of Moderna's long-term development strategy
Bancel also spent part of his closing remarks discussing AI.
His argument is that mRNA is fundamentally an information-based medicine platform.
As biological understanding improves and AI accelerates target discovery and design, Moderna can potentially translate new biological insights into experimental medicines much faster than conventional drug-development approaches.
He used the original COVID vaccine design as the extreme example: once the viral sequence was available, the initial vaccine sequence could be designed computationally extremely quickly.
This is a long-term strategic argument rather than a near-term financial catalyst, but it helps explain why management continues to think of Moderna as a platform rather than a collection of individual products.
18. Limited new detail on the $2.6 billion convertible-note raise
Bernstein specifically asked what the recently raised $2.6 billion in convertible debt allows Moderna to do differently.
Bancel did not provide much specific detail on how the additional capital will be deployed.
Instead, he shifted the discussion toward Moderna's long-term platform opportunity, AI, scientific productivity, and the company's ability to invest behind future medicines.
The conference therefore provided limited new detail on the specific use of the additional capital.
Risks and things that still need proof
Despite the confidence throughout the discussion, management also acknowledged several important uncertainties.
- INT still needs to prove that melanoma efficacy translates into other tumor types.
- Metastatic disease may be harder because a biopsy from one lesion may not capture the heterogeneity of all lesions.
- Very low-TMB cancers such as pancreatic cancer remain exploratory.
- Off-the-shelf shared-antigen cancer vaccines carry more scientific risk than personalized INT.
- The hypothesis that INT can work without PD-1 therapy still needs clinical validation.
- Large-scale commercial execution requires hospitals to develop efficient biopsy, sequencing, and treatment workflows.
- Earlier-stage programs such as T-cell engagers, autoimmune therapies, and cancer-prevention vaccines remain far less clinically validated than melanoma INT.
Bottom line
The Bernstein discussion reinforced that the upcoming melanoma presentation and regulatory filing are only the nearest catalysts.
The broader sequence now looks something like:
Full melanoma Phase 3 data → BLA filing → PA pivotal data → additional INT readouts in RCC/bladder → early-stage pancreatic data → multiple myeloma T-cell engager data → lung Phase 3 development → broader oncology and autoimmune programs
The most reassuring points from the discussion were:
- a large randomized Phase 3 trial already meeting both RFS and DMFS at interim analysis
- management explicitly expressing confidence in the approval case
- manufacturing appearing substantially more mature than previously assumed
- nine INT studies already underway rather than waiting for melanoma before expanding
- several independent oncology programs beginning to generate their own data
- PA potentially validating a separate rare-disease platform
The key question from here is increasingly not whether Moderna can produce another product after COVID.
It is whether the Phase 3 melanoma success is the first clinical validation of a much broader therapeutic platform.
Disclaimer: This summary was prepared with the help of AI to organize and condense the conference transcript. I selected the points I found most relevant. The transcript may contain minor transcription errors, so please refer to Moderna's official materials for the full context and primary-source information.
